Predict your next investment

HEALTHCARE | Biotechnology
kobiolabs.com

See what CB Insights has to offer

Founded Year

2014

Stage

IPO | IPO

Total Raised

$35.99M

Date of IPO

11/18/2020

Market Cap

536.56B

About KoBioLabs

KoBioLabs is developing solutions in microbiome analysis, probiotics, and microbiome therapeutics. The company researches the specific genetic sequences of the gut microbiome related to these diseases and uses this genetic information to develop a pathogenic or therapeutic microbial biomarker. Its objective is to use these biomarkers to evaluate the healthy gut microbial community and develop a rapid and precise diagnostic technology.

KoBioLabs Headquarter Location

Seoul National University, Bio-MAX, #220, Room 630 1, Gwanak-ro, Gwanak-gu

Seoul, 08826,

South Korea

+82 02)888-9964

Latest KoBioLabs News

Securities firms' burden on biopharma companies' IPO

Dec 2, 2020

Posted : 2020-12-02 16:51 By Anna J. Park Market interests and profitability of biopharma companies have exponentially grown over the course of the ongoing global pandemic. This year alone, 21 newly listed firms out of 65 IPO cases are biopharmaceutical companies, drawing in a large amount of money for stock allotment from the IPO process. Some of the most successful IPO bio companies this year include SK Biopharmaceuticals, SCM Lifescience, Korea Pharma, Dream CIS, Gencurix, Kobiolabs and more. More bio companies are set to launch IPOs in December as well, such as Genome & Company and Prestige Biopharma. Despite the ever-increasing number of bio-related companies in the country and their rosy growth potential in the near future, securities firms are having difficulties in dealing with the IPO process of these businesses due to lack of expertise in the bio sector. Only qualified employees with an academic background in life sciences and pharmaceuticals to at least a master's or doctorate degree level could understand bio-related companies' detailed business plans based on different stages of clinic trials and new drug pipelines. That's why those with bio and medical knowledge at securities firms are hired mostly as bio industry analysts. However, when it comes to the IPOs of new bio firms, industry sources say securities firms are experiencing a dilemma as to whether to take an underwriter's role in their initial public offering process. It is a market that they should not neglect, yet due to lack of finance-educated staff with bio expertise, their burden grows heavier. In other words, as only a few qualified employees understand bio companies' business plans and the accuracy of their outlooks, IPO-specialized staff, who mostly have academic backgrounds in finance and management, are having difficulties in evaluating exact values of bio firms and coming up with appropriate initial offering prices. Bio firms wish to raise the offering prices, but securities firms' IPO experts are having difficulty in setting a solid price that accurately reflects the potential of the sector. For the past three to four years, securities firms have put significant effort into securing IPO deals with fledging bio companies. The vigorous moves around the sector's public offerings have also been buttressed by the state-run bourse exchange's special listing track that is open to companies with technical growth potential. If only guaranteed by IPO underwriter companies, new bio companies could raise public money through the listing. From 2005 to 2019, 87 companies have been listed at KOSDAQ through the special listing track, and 67 of those businesses are bio companies. As they cannot give up on the newly-growing field, it is now a must for underwriters to run their own bio team in order to have a chance to win contracts for bio firms' IPOs. Large securities firms are running bio-focused teams, yet smaller companies are not experienced enough or don't have enough staff to excel in the sector's IPO process. Thus smaller securities firms are faced with increasing costs to back up these teams in order to avoid being left behind, while the chances of them being selected by bio companies gets slimmer and slimmer due to their lack of a track record.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing KoBioLabs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KoBioLabs is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Microbiome

274 items

M

Medical Devices

7,870 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

14,139 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health Monitoring & Diagnostics

3,092 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

KoBioLabs Patents

KoBioLabs has filed 5 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/23/2020

10/12/2021

Clusters of differentiation, Allergology, Immunology, Immune system, Autoimmune diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/23/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/12/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Allergology, Immunology, Immune system, Autoimmune diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

KoBioLabs Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

KoBioLabs Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.